The Month in Cervical Cancer Research

April brought a wide range of cervical cancer research, with the strongest open-access evidence concentrated in three areas: immunotherapy combinations for people with recurrent or metastatic disease, a landmark modeling study on how the United States should adapt its screening guidelines for a partly-vaccinated population, and a sustained focus on the equity gaps that remain the defining obstacle to eliminating a cancer the world now has the tools to prevent. The treatment landscape for advanced disease continues to evolve rapidly, with new data on how to compare available regimens and how to predict who will benefit from them. At the same time, research from Ukraine, Nigeria, Australia, Canada, Uganda, and China makes clear that the question of who can actually access cervical cancer prevention is as urgent as the question of what the best prevention looks like.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

The treatment landscape for recurrent and metastatic cervical cancer continues to evolve and new evidence shows how to navigate it

For people whose cervical cancer has returned or spread to other organs, the past several years have produced more new treatment options than the previous two decades combined. Immune checkpoint inhibitors (drugs that remove a natural brake on the immune system, helping it recognize and attack cancer cells) are now standard in first-line treatment for many people. A network meta-analysis published in Frontiers in Immunology gives clinicians and patients the most comprehensive head-to-head comparison of available regimens to date.

• Researchers analyzed four phase III randomized controlled trials encompassing 1,924 people with persistent, recurrent, or metastatic cervical cancer. Their key finding: in treatment settings that include bevacizumab (a drug that blocks blood vessel growth, cutting off the tumor's supply lines) combined with either pembrolizumab or atezolizumab (both immune checkpoint inhibitors) performed comparably and were significantly superior to chemotherapy alone. In settings without bevacizumab, cadonilimab (a newer bispecific antibody that simultaneously blocks two immune checkpoints, PD-1 and CTLA-4) outperformed pembrolizumab on survival trends and was the only regimen to show a meaningful benefit in people whose tumors do not express the PD-L1 protein marker, a group that typically responds poorly to checkpoint inhibitors. For patients and clinicians, this provides the clearest available roadmap for treatment selection, including the finding that PD-L1 expression status (a marker now testable in most oncology centers) should inform the choice of regimen. (Read the full paper)
• A practical question that follows from checkpoint inhibitor therapy is who will respond and for how long. Researchers studied 148 people with recurrent or metastatic cervical cancer treated with immune checkpoint inhibitors at a single center. They developed a prognostic nomogram (a visual calculation tool that combines multiple factors into a personalized risk estimate) built around the neutrophil-to-lymphocyte ratio (NLR), a widely available blood test that reflects the balance between inflammatory and immune cells. The combined NLR measure, which tracked the ratio before and after treatment, emerged as an independent predictor of how long people remained without disease progression. The nomogram incorporating NLR, tumor histology, PD-L1 expression, prior treatment lines, and metastatic burden achieved good predictive accuracy. This kind of bedside tool has practical value: it uses tests already done in routine care to give a more individualized forecast of how treatment will go. (Read the full paper)
• A published case report describes the first reported response to ivonescimab (a novel tetravalent bispecific antibody that simultaneously targets PD-1, which blocks immune responses against cancer, and VEGF-A, which drives tumor blood vessel formation) in recurrent or metastatic cervical cancer following failure of first-line immunotherapy. A patient with cervical squamous cell carcinoma and liver metastases achieved a partial response to ivonescimab combined with albumin-bound paclitaxel after progressing on first-line cadonilimab, bevacizumab, and chemotherapy. While a single case report does not establish efficacy, it represents the first clinical evidence of activity for this dual-mechanism agent in this setting and points toward a possible direction for later-line treatment. The patient experienced only low-grade side effects throughout. (Read the full paper)

Immunotherapy added before surgery is showing real promise for people with locally advanced disease

Locally advanced cervical cancer (disease that has grown beyond the cervix into nearby tissue but has not yet spread to distant organs) is typically treated with concurrent chemotherapy and radiation. Adding immunotherapy before or during this treatment is an active area of investigation.

• A real-world analysis examined 89 people with locally advanced cervical cancer who received neoadjuvant chemoimmunotherapy (chemotherapy combined with an immune checkpoint inhibitor given before surgery) followed by radical hysterectomy between 2022 and 2025. Of these, 35.9% achieved an optimal pathological response, meaning either complete disappearance of tumor at surgery (20.2%) or near-complete disappearance (15.7%). Over a median follow-up of 13 months, estimated two-year disease-free survival in this group was 90.7%, with no deaths. Serious treatment-related side effects occurred in 21.9% of patients, and none were life-threatening. The authors suggest that people who achieve this degree of tumor response may be candidates for less intensive follow-up treatment, an important quality-of-life consideration. These findings are encouraging but come from a single center and a short follow-up window; larger prospective studies are needed. (Read the full paper)
• For people with locally advanced cervical cancer receiving radical radiotherapy (high-dose radiation aimed at curing the disease), knowing in advance who is at higher risk of recurrence can help guide treatment decisions. Researchers studied 300 such patients and found that a panel of systemic immune-inflammation markers derived from routine blood tests, when incorporated into a nomogram and a machine learning model, could predict survival outcomes at one to five years with good accuracy. The logistic regression machine learning model outperformed the traditional nomogram in shorter-term prediction. While this remains a tool for clinicians rather than patients to act on directly, it illustrates how ordinary blood test results, already collected as part of cancer care, can be used to refine risk estimates and support treatment planning. (Read the full paper)

US cervical cancer screening guidelines are overdue for an update, and new modeling shows what the optimal approach looks like for vaccinated populations

The United States' current screening guidelines were designed for a population that had not yet been vaccinated against HPV. As vaccinated cohorts enter the age of recommended screening, those guidelines may be recommending more frequent testing than is necessary for some people and possibly less-optimal testing approaches for others.

• A landmark comparative modeling study used three independent simulation models to evaluate 92 cervical cancer screening strategies for three distinct US birth cohorts: women born in 1980 who were not vaccinated, women born in 1993 who received the earlier bivalent or quadrivalent HPV vaccine, and women born in 2003 who predominantly received the newer nine-valent vaccine (Gardasil 9, which covers more HPV strains). The finding was consistent across all three models and all three cohorts: primary HPV testing (testing for the HPV virus itself, rather than looking for abnormal cells) is the best screening approach regardless of vaccination history. But the optimal screening interval differs considerably. For the unvaccinated 1980 cohort, the modeling found that HPV testing every five years starting at age 25 is cost-effective and effective. For the 1993 cohort (partially protected by earlier vaccines), eight-yearly testing from age 25 is optimal. For the 2003 cohort with nine-valent vaccine protection, testing every ten years starting at age 27 performs best. These findings have direct implications for US guidelines, which have not yet been differentiated by vaccination cohort. (Read the full paper)
• A modeling study provides a complementary perspective from China, where vaccine supply constraints and screening infrastructure challenges have shaped different tradeoffs. Their mathematical model found that combining HPV vaccination and screening is more cost-effective than either approach alone. Among screening methods, HPV testing was more cost-effective than cytology, while AI-assisted thin-layer cytology (a computer-aided approach to reading cervical cell samples) outperformed all traditional methods in the model. On vaccination, they found that offering a single dose of the bivalent HPV vaccine to girls under 14, and redirecting surplus doses to women under 25, produced a lower cost per quality-adjusted life year than two- or three-dose schedules. These findings support the global evidence base for single-dose vaccination as a tool for expanding coverage where doses are limited. (Read the full paper)

HPV self-sampling is proving its worth in the most challenging settings imaginable

Self-sampling for HPV, where a person collects their own cervicovaginal sample at home or in a private space and mails or brings it to a laboratory, has been steadily building an evidence base as a way to extend cervical cancer screening to people who face barriers to clinic-based testing. This month's research tested it under conditions that underscore just how robust the approach can be.

• A pilot implementation study describes HPV self-sampling for cervical cancer screening in Zaporizhzhia Oblast, Ukraine, a region under active armed conflict, between April and December 2025. Of 589 distributed self-sampling kits, 572 samples were returned and analyzed, a 96.5% return rate. Only four of 593 people declined to participate (0.67%). Overall, 9.1% of participants tested positive for high-risk HPV types, and all women testing positive for HPV16/18 (the two strains responsible for most cervical cancers) were contacted, referred, and seen by a specialist within two months. Median turnaround time from self-sampling to results was 6.3 days. All participant feedback was positive. This study demonstrates that self-sampling can be initiated and sustained in conditions of active war, population displacement, and disrupted health services and that high engagement is achievable even in settings of extreme stress. (Read the full paper)
• What drives decisions about self-sampling? Researchers in China conducted a discrete choice experiment, which is a survey methodology that asks people to choose between options that vary on specific attributes, allowing researchers to measure how much each attribute matters. Among 200 participants, accuracy was by far the most important attribute (accounting for 42.6% of the decision weight), followed by price, sampling time, procedural difficulty, and comfort. A single key message for implementation: accuracy and affordability matter most to people who are deciding whether to self-sample. Tailoring programs to communicate high accuracy and minimize cost could substantially increase uptake, particularly in communities that are currently underscreened. (Read the full paper)
• A cross-sectional study in Ibadan, Nigeria surveyed 620 women about preferences between self-sampling and provider-collected samples. The results were nearly even: 51.6% preferred provider collection and 48.4% preferred self-sampling overall, but in urban areas self-sampling was preferred by a majority (53.7%), while peri-urban people more often preferred provider collection (56.6%). Urban people cited privacy and comfort as reasons for preferring self-sampling; peri-urban people cited trust in clinical expertise. The study suggests that self-sampling works best as a complementary option integrated into existing services rather than a replacement for provider-based care, especially in settings where trust in clinical staff remains a meaningful driver of participation. (Read the full paper)

HPV vaccination still isn't reaching everyone, and new research shows who falls through the gaps

The HPV vaccine is one of the most powerful cancer prevention tools in existence: it prevents most cervical cancers, as well as HPV-related cancers of the vulva, vagina, anus, and throat. But uptake remains uneven, and new data this month reveals the populations most at risk of being left behind.

• A study surveyed 428 out-of-school girls aged 9-20 years in inland and fishing communities near Masaka, Uganda. Cervical cancer accounts for 80% of female cancer cases in Uganda, yet vaccination programs primarily reach girls through schools, structurally excluding out-of-school girls, who are often from higher-risk backgrounds (62.4% of study participants reported prior sexual experience). Fewer than half of participants (44.2%) had any prior knowledge of the HPV vaccine, and only 29.9% had received at least one dose. Crucially, 91.2% of unvaccinated girls expressed willingness to receive the vaccine when offered. The single strongest predictor of uptake was prior awareness - having heard of the vaccine at all. Community outreach was the preferred delivery strategy. This study makes the case that reaching out-of-school girls requires intentional, community-based delivery programs that do not depend on school attendance as the gatekeeping mechanism. (Read the full paper)
• A systematic review examined HPV vaccination in non-HIV immunocompromised individuals: people with conditions such as solid organ transplants, lupus, or other autoimmune diseases who are at elevated risk for HPV-related disease but are often excluded from standard vaccination programs or not actively offered the vaccine. Drawing on 24 studies, the review found that the vaccine generates a strong antibody response in most immunocompromised individuals (median seropositivity of 95.8% at seven months) and that serious adverse events were rare and not attributed to vaccination. Evidence on whether vaccination actually reduces cervical precancer in this group is limited, but immunogenicity and safety data are encouraging. The authors call for targeted studies in specific immunocompromised subgroups to fill this evidence gap. In the meantime, this review supports discussing HPV vaccination with immunocompromised patients who have not been vaccinated. (Read the full paper)
• A qualitative study in Kuwait interviewed 20 parents and guardians about their knowledge of and attitudes toward HPV vaccination using the Health Belief Model framework. Seven main themes emerged, with perceived barriers being the richest, including stigma related to the vaccine's association with sexual transmission, religious considerations about introducing adolescents to information about sexually transmitted infections, and concerns about safety and efficacy. At the same time, positive signals from healthcare practitioners and clear educational messages about the cancer-prevention benefits of vaccination emerged as the most powerful factors that could overcome these barriers. Kuwait does not yet have a national HPV immunization program; this study provides direct evidence about what a culturally attuned communication strategy would need to address to successfully introduce one. (Read the full paper)

Closing the equity gap in cervical cancer screening remains the defining challenge of elimination

The WHO's global strategy to eliminate cervical cancer depends on three targets: 90% of girls vaccinated by age 15, 70% of women screened by age 45, and 90% of women with detected disease receiving treatment. New research from four continents makes it clear how far most of the world remains from the screening target and what it would actually take to close the gap.

• A multilevel analysis drew on nationally representative data from 148,605 women aged 30-49 in 20 low- and middle-income countries. Overall cervical cancer screening uptake was just 14%, ranging from under 1% in Mauritania to 43% in Zambia. Key factors associated with higher screening were access to a health facility in the past year, media exposure, community-level education, and employment. Rural residence and poverty were consistently associated with lower uptake. The message for policymakers is direct: integrating cervical cancer screening into routine reproductive and maternal care, the contact points where women already engage with the health system, and investing in community education and media campaigns are the interventions most likely to move the needle at scale. (Read the full paper)
• A qualitative study explored why screening rates remain so low in rural northeastern Uganda. Through six focus group discussions and nine key informant interviews with community members and health workers in Ngora district, they identified a mix of supply-side and demand-side barriers: myths and misconceptions about what cervical cancer screening involves, long distances to health facilities, stock-outs of essential supplies, an insufficient health workforce, and informal costs charged by facilities despite services being nominally free. Community sensitization, national policy support, and integration of screening with other services were identified as effective facilitators. Broad awareness campaigns are helpful, but they do not address the structural barriers (distance, cost, supply chains) that prevent women from following through. (Read the full paper)
• A study protocol describes the Screen Your Way study, designed to embed HPV self-collection models into Aboriginal Community Controlled Health Organisations (ACCHOs) across Australia. In 2022, HPV self-collection became available to all participants in Australia's National Cervical Screening Program; Screen Your Way will co-design, implement, and evaluate how to make that option genuinely accessible for Aboriginal and Torres Strait Islander women and people with a cervix, who remain disproportionately under-screened. The study will use an Indigenist implementation research approach, meaning that community priorities and governance guide every stage of design and evaluation. This is important not only as an Australian equity project but as a model for how self-collection programs can be adapted for specific communities rather than simply made available and assumed to be accessible. (Read the full paper)
• An equity analysis of Uganda's 2022 Demographic and Health Survey found significant pro-rich inequality in both awareness of cervical cancer screening and its utilization. Wealthier women were disproportionately more likely to have been screened and to know that screening exists, the opposite of what an equitable health system would look like, where services go preferentially to those with greatest need. Pro-rich inequality was more pronounced in urban areas than rural ones, suggesting that urban health systems in Uganda are structured in ways that favor those who already have resources. The authors call for deliberate reallocation of outreach and services toward the poorer and more rural women who bear the highest burden of disease. (Read the full paper)

What qualitative research tells us about what barriers actually look like, from the Arctic to AI adoption

Numbers can show that screening rates are low or vaccination uptake is uneven. Qualitative research shows why in terms that matter for designing real solutions.

• A qualitative study used sharing circles and interviews with healthcare professionals, community members including Elders, and community leaders in two remote Indigenous communities in Canada's Northwest Territories. Four categories of barrier to utilizing cancer screening were identified: socio-environmental (geographic isolation, limited resources), socio-cultural (the legacy of colonial practices and persistent mistrust of the health system, fear, and limited cultural safety of services), socio-political (a history of health interventions experienced as extractive), and personal factors including fear of diagnosis. The suggested approaches to encourage screening were community outreach, collaboration with local leadership, sustainability, cultural safety, and greater support for healthcare professionals working in remote settings. These findings are directly relevant to any effort to extend cervical cancer screening to isolated and historically underserved communities. (Read the full paper)
• A qualitative study interviewed key managers and implementers of China's first provincial-level AI-assisted population-wide cervical cancer screening program in Hubei province, a program serving 12.67 million eligible women. Government stewardship emerged as the core driver of achieving near-universal coverage: without coordinated government leadership securing funding, procurement, and multi-sectoral collaboration, the AI technology itself would not have been sufficient. Structural factors (trained personnel, information systems), process factors (quality control, community mobilization), and outcome factors (coverage and follow-up rates) all depended on government architecture. This has broad implications: AI-assisted screening is increasingly available and accurate, but technology alone does not produce coverage. The organizational and governmental infrastructure to deploy it equitably is the harder problem to solve. (Read the full paper)

What Does This Mean for Me?

If your cervical cancer has returned or spread, the network meta-analysis published this month in Frontiers in Immunology offers the most comprehensive comparison of available first-line regimens to date. It suggests that the optimal treatment choice may depend on whether bevacizumab is an option for you, and whether your tumor expresses the PD-L1 protein, a marker that can be tested on a biopsy sample. If you haven't asked your oncologist about PD-L1 testing or about how the specific regimen you're on was chosen relative to the alternatives, this is a good moment to do so. The field is moving quickly, and asking "is there a regimen comparison that would help us decide?" is a well-grounded question to bring to your care team.

If you have locally advanced cervical cancer, disease that has grown beyond the cervix but hasn't spread to distant organs, immunotherapy is now being investigated as a possible addition to the standard treatment of radiation and chemotherapy, or before surgery in people who will have a radical hysterectomy. A real-world study published this month found that more than a third of people who received chemotherapy plus an immune checkpoint inhibitor before surgery had near-complete or complete disappearance of tumor at the time of surgery, with encouraging short-term survival outcomes. These are early findings from a single center, and neoadjuvant chemoimmunotherapy before surgery is not yet standard of care in most settings. If you are in treatment or recently diagnosed, it is worth asking your team whether clinical trials evaluating immunotherapy additions are available to you. You can also search for clinical trials on the OCRA website.

If you are thinking about or overdue for cervical cancer screening, primary HPV testing (testing for the virus itself, rather than looking for abnormal cells under a microscope) is the recommended approach regardless of your vaccination history.

If you are thinking about HPV vaccination for yourself or someone in your life, the evidence keeps strengthening. The vaccine prevents the virus responsible for nearly all cervical cancers, and this month's systematic review supports that it is both immunogenic and safe for people with autoimmune conditions or organ transplants, a population often excluded from standard vaccination programs but at elevated risk for HPV-related disease. If you or someone you care for is immunocompromised and hasn't been vaccinated, it is worth asking a healthcare provider whether vaccination is appropriate. For younger people, the evidence from Uganda and Kuwait this month reinforces what the field has long shown: the most important factor in vaccine uptake is simply knowing it exists. If you know young people who haven't been vaccinated, a conversation about it matters.

Research that benefits the full global community, including the 90% of cervical cancer deaths that occur in low- and middle-income countries, depends on people who advocate, participate in clinical trials, and help ensure that advances reach those who need them most. Visit ocrahope.org to learn about OCRA's resources and how to connect with the gynecologic cancer community.

OCRA has a wealth of patient education and support programming, including programs specifically for cervical cancer patients. Click here to learn more.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

Directly Referenced in This Digest

• Wang X, Zhang Y, Wang C, et al. "Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy." Frontiers in Immunology. April 16, 2026. PMID 42079658. https://doi.org/10.3389/fimmu.2026.1789532
• Xu Z, Zhang L, Wang H, et al. "Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors." Frontiers in Immunology. April 14, 2026. PMID 42058197. https://doi.org/10.3389/fimmu.2026.1811428
• Xu M, Qiu S, Zhou J, Zhang Y. "Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: a case report and literature review." Human Vaccines & Immunotherapeutics. April 21, 2026. PMID 42012232. https://doi.org/10.1080/21645515.2026.2632451
• Zhao L, Zhai Q, Zhang W, et al. "Favorable short-term survival in locally advanced cervical cancer with optimal pathological response after neoadjuvant chemoimmunotherapy: a real-world analysis." Frontiers in Immunology. April 7, 2026. PMID 42023238. https://doi.org/10.3389/fimmu.2026.1737081
• Li Y, Han J, Xiao S, et al. "Prognostic utility of systemic immune-inflammation markers in locally advanced cervical cancer undergoing radical radiotherapy." The Oncologist. April 10, 2026. PMID 42015386. https://doi.org/10.1093/oncolo/oyag139
• de Bondt DD, Simms KT, Naslazi E, et al. "Optimal cervical cancer screening strategies for unvaccinated and HPV-vaccinated cohorts in the United States: a comprehensive comparative modeling analysis." Lancet Regional Health. Americas. April 17, 2026. PMID 42022232. https://doi.org/10.1016/j.lana.2026.101474
• Li Y, Lin YF, Cai B, et al. "Modelling the epidemic dynamics of HPV among women in China and optimization of ongoing cervical cancer elimination strategies." BMC Medicine. April 22, 2026. PMID 42021319. https://doi.org/10.1186/s12916-026-04881-1
• Kovalyov O, Kovalyov K, Deinichenko O, Dillner J, Arroyo Mühr LS. "HPV self-sampling for cervical cancer screening during wartime: a pilot implementation study from a conflict-affected region of Ukraine." BMJ Global Health. April 28, 2026. PMID 42049387. https://doi.org/10.1136/bmjgh-2026-023478
• Ding N, Chen Y, Zhou X, et al. "Women's preferences for HPV self-sampling in cervical cancer screening: a discrete choice experiment." Frontiers in Public Health. April 13, 2026. PMID 42052012. https://doi.org/10.3389/fpubh.2026.1779443
• Andrew-Bassey UI, Bello YO, Okunlola MA, Morhason-Bello IO. "Women's preferences and concerns on HPV screening sampling methods for cervical cancer in Ibadan, Nigeria: a cross-sectional study." BMJ Open. April 27, 2026. PMID 42044966. https://doi.org/10.1136/bmjopen-2025-110692
• Kitonsa J, Kafeero P, Ankunda V, et al. "Knowledge, perceptions, uptake, and determinants of HPV vaccination, and preferred delivery strategies among out-of-school girls in Masaka, Uganda." Human Vaccines & Immunotherapeutics. April 2, 2026. PMID 41928392. https://doi.org/10.1080/21645515.2026.2654928
• Kapp P, Siemens W, Gorenflo L, et al. "Effectiveness, immunogenicity and safety of human papillomavirus vaccination in non-HIV immunocompromised individuals: a systematic review." EClinicalMedicine. April 11, 2026. PMID 42011219. https://doi.org/10.1016/j.eclinm.2026.103865
• Abuzoor A, Jabin MSR, Jonker C. "Health Beliefs and Perspectives of Parents Regarding Human Papillomavirus Vaccination in Kuwait: Qualitative Study." JMIR Formative Research. April 2, 2026. PMID 41927043. https://doi.org/10.2196/85438
• Bitewa MD, Yewodiaw TK, Abneh AA, et al. "Determinants of cervical cancer screening among women aged 30 to 49 years in 20 low- and middle-income countries: A multilevel analysis." PLoS One. April 24, 2026. PMID 42030334. https://doi.org/10.1371/journal.pone.0347837
• Mutyaba I, Akurut H, Nabaasa R, et al. "Facilitators and Barriers to Cervical Cancer Screening Among Women in a Rural District of Northeastern Uganda, a Qualitative Study." Cancer Management and Research. April 23, 2026. PMID 42052441. https://doi.org/10.2147/CMAR.S598738
• Whop LJ, Mitchell LE, Butler TL, et al. "Screen Your Way Study Protocol: Embedding community driven models to increase cervical screening via HPV self-collection to improve cervical cancer outcomes for Aboriginal and Torres Strait Islander people." PLoS One. April 22, 2026. PMID 42018577. https://doi.org/10.1371/journal.pone.0336004
• Emesu G, Kiracho EE, Jatho A, et al. "Equity in awareness and utilization of cervical cancer screening services among women of reproductive age in Uganda: Analysis of vertical equity using evidence from UDHS 2022." PLoS One. April 7, 2026. PMID 41945595. https://doi.org/10.1371/journal.pone.0335336
• Kolahdooz F, Jang SL, Yi KJ, et al. "Barriers and facilitators to the utilization of cancer screening services in two Arctic Indigenous communities in Canada." Global Health Action. April 20, 2026. PMID 42003703. https://doi.org/10.1080/16549716.2026.2657081
• Ji L, Zhou X, Yao L. "Factors Influencing Universal Coverage of AI-Assisted Cervical Cancer Screening: Qualitative Study Based on the Macro Model of Health System." Journal of Medical Internet Research. April 1, 2026. PMID 41921107. https://doi.org/10.2196/75372

Additional Open-Access Papers Published in April 2026 on Related Topics

• Ługowski F, Papież M, Suchońska B. "Comparative Efficacy of Treatment Methods and Risk Factors for Treatment Failure in High-Grade Vaginal Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis." Cancers (MDPI). April 20, 2026. PMID 42073625. https://doi.org/10.3390/cancers18081302 (Systematic review and meta-analysis of treatment options for high-grade vaginal intraepithelial neoplasia (VaIN 2+) - a precancerous condition closely related to cervical disease. Immunosuppression was the strongest risk factor for treatment failure; ablative and surgical methods outperformed topical agents.)
• Luca DC, Cirimbei C, Ionescu SO, et al. "Global and Regional Diagnostic Results of Progress Toward Cervical Cancer Elimination, According to the WHO Strategy: A Systematic Review." Diagnostics (MDPI). April 20, 2026. PMID 42072849. https://doi.org/10.3390/diagnostics16081224 (Systematic review of 47 studies assessing global progress toward the WHO cervical cancer elimination strategy. Found considerable regional disparities, with Eastern Europe, parts of Asia, and sub-Saharan Africa below WHO targets on vaccination, screening, and treatment.)
• Satoh M, Sato N. "Participation in Cervical and Breast Cancer Screening Among Working Women in Japan: Panel Survey Study." JMIR Cancer. April 28, 2026. PMID 42048492. https://doi.org/10.2196/86885 (Panel survey study using national Japanese household data finding that certain personality traits - higher conscientiousness and neuroticism - were paradoxically associated with lower cancer screening attendance, suggesting that anxiety and fear of results can override health-promoting behavior.)
• Assefa KT, Worku AG, Muche AA, et al. "Geographic inequities in human papillomavirus vaccine non-uptake and its determinants among adolescent girls in Ethiopia: Evidence from the National Immunization Survey." PLoS One. April 28, 2026. PMID 42048332. https://doi.org/10.1371/journal.pone.0348076 (Geospatial analysis of HPV vaccine non-uptake in Ethiopia (46% non-uptake overall), mapping regional clusters of low coverage concentrated in eastern Amhara, eastern Oromia, and parts of Somali region, driven by poor knowledge and not living with parents.)
• Pruski D, Millert-Kalińska S, Żurawski J, et al. "The use of the HPV vaccine in a group of primarily unvaccinated HPV-positive patients." Human Vaccines & Immunotherapeutics. April 28, 2026. PMID 42047045. https://doi.org/10.1080/21645515.2026.2664310 (Study of 461 HPV-positive women (351 vaccinated, 110 controls) finding that nine-valent HPV vaccination significantly increased HPV clearance and complete remission rates in previously unvaccinated HPV-positive adults, supporting extending vaccination to this group as an adjunct to standard care.)
• Gungor Serin B, Temiz BE, Tuncer H, et al. "Association of Oral Papivir/Pavirona Supplementation with HPV DNA Clearance." Viruses (MDPI). April 9, 2026. PMID 42043244. https://doi.org/10.3390/v18040455 (Retrospective cohort study from Hacettepe University finding higher HPV clearance rates at 6 and 12 months among women who took an oral supplement (Papivir/Pavirona) compared to controls. Results are preliminary and the supplement is not yet validated or recommended; independent replication is required before any clinical conclusions can be drawn.)
• Jiang Y, Cui Y, Su D, et al. "Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review." Frontiers in Endocrinology. April 14, 2026. PMID 42058780. https://doi.org/10.3389/fendo.2026.1819809
• Lu S, Liu K, Luo W, Zheng S. "PD-L1 expression patterns in stage IB1 cervical squamous cell carcinoma: a retrospective study on implications for tumor budding and immune microenvironment." PeerJ. April 22, 2026. PMID 42038463. https://doi.org/10.7717/peerj.21052 (Retrospective pathology study identifying three distinct PD-L1 expression patterns in early-stage cervical squamous cell carcinoma and describing their associations with tumor budding, lymph node metastasis, and immune cell infiltration - potentially relevant to predicting immunotherapy response.)
• Tilahun SW, Nega A, Wagaw L, Addissie A. "Shared decision-making in Cervical Cancer Care at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A mixed-methods study." PLoS One. April 24, 2026. PMID 42030302. https://doi.org/10.1371/journal.pone.0348172 (Mixed-methods study of shared decision-making in cervical cancer care at Ethiopia's main cancer hospital, finding that trust in oncologists was the strongest positive predictor, while rural residence, unemployment, and paradoxically higher health literacy were associated with lower perceived involvement in decisions.)
• Khan SU, Halawi MH, Almehmadi M, et al. "Innate immune recognition and microenvironmental reprogramming in HPV-induced cervical cancer: from pattern recognition receptor activation to immune tolerance disruption." Frontiers in Cellular and Infection Microbiology. April 7, 2026. PMID 42022798. https://doi.org/10.3389/fcimb.2026.1758873 (Mechanistic review of how the innate immune system detects HPV infection and how HPV evades these defenses - foundational science for understanding why some infections persist and become cancerous, with implications for vaccine and immunotherapy development.)
• Waseem S, Zhan J, Xiao X, Bai P. "Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance." Frontiers in Oncology. April 7, 2026. PMID 42022325. https://doi.org/10.3389/fonc.2026.1785469 (Broad review of precision oncology approaches across endometrial, ovarian, and cervical cancers, including molecular classification frameworks, approved targeted agents such as tisotumab vedotin and immune checkpoint inhibitors for cervical cancer, and mechanisms of treatment resistance.)
• Lee-Foon NK, Lofters A, Dias K, et al. "EMPOWHPVR: exploring the factors that impact HPV self-sampling uptake amongst Black women and people with a cervix in Peel region, Ontario - a qualitative study protocol." BMJ Open. April 22, 2026. PMID 42020121. https://doi.org/10.1136/bmjopen-2025-110930 (Protocol for a community-led qualitative study co-designed with Black women and people with a cervix in Ontario to understand barriers and facilitators to HPV self-sampling uptake in this underscreened population, as a foundation for developing a tailored intervention.)
• Özbey G, Aytaç S. "A multimodal scanning electron microscopy-atomic force microscopy images for early cervical cancer detection using discrete wavelet transform-derived features and divergence-based classification." Revista da Associação Médica Brasileira. April 20, 2026. PMID 42018846. https://doi.org/10.1590/1806-9282.20251173 (Technical imaging study combining scanning electron microscopy and atomic force microscopy with wavelet-based machine learning for early cervical cancer cell classification; achieved 95.9% accuracy in a laboratory setting. Preclinical; no near-term clinical application yet.)
• Sabale U, Cherif A, Valente S, et al. "Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study." Human Vaccines & Immunotherapeutics. April 22, 2026. PMID 42017894. https://doi.org/10.1080/21645515.2026.2651503 (Modeling study estimating that 42-72% of disease-causing HPV infections in Nordic/Baltic women occur after age 26, and 8-21% after age 45, supporting consideration of HPV vaccination in older unvaccinated adults who remain at risk for precancerous lesions.)
• Infante V, Miyaji KT, Martini CCR, et al. "Human papillomavirus (HPV) seroprevalence, cervical HPV prevalence and cervical lesions in systemic lupus erythematosus (SLE) and immunocompetent women." Lupus Science & Medicine. April 9, 2026. PMID 41956714. https://doi.org/10.1136/lupus-2025-001812 (Cross-sectional study from São Paulo comparing 122 women with SLE and 132 immunocompetent women, finding higher cervical HPV prevalence, higher HPV-related lesion rates, and higher vaccine-type HPV antibody levels in the SLE group - supporting early and targeted vaccination and screening for women with autoimmune disease.)
• Azubuike S, Adamu M. "Cervical cancer screening uptake and its determinants among rural women in North Central Nigeria: a cross-sectional study." Rural and Remote Health. April 7, 2026. PMID 41947640. https://doi.org/10.22605/RRH10433 (Community-based study of 416 rural women in Kogi State, Nigeria, finding 12.2% screening uptake despite 36% expressing willingness to be screened. Knowledge gaps, lack of symptoms, and low perceived susceptibility were primary barriers.)
• Amadi A, Lawal M, Khan H, Japhet S. "Bridging the gap: exploring healthcare professionals' perceptions and barriers towards cervical cancer screening services uptake amongst women in rural communities." Journal of the Egyptian National Cancer Institute. April 6, 2026. PMID 41936692. https://doi.org/10.1186/s43046-026-00346-x (Qualitative study examining healthcare professionals' perspectives on cervical cancer screening barriers in rural communities, identifying provider-level factors including training gaps, resource constraints, and systemic challenges as contributing to low uptake.)
• Nemeth Blažić T, Zhu Q, Cahun E, Nola IA. "Developing a digital interactive tool to enhance cervical cancer awareness and health literacy in Croatia: a community case study." Frontiers in Public Health. April 13, 2026. PMID 42052027. https://doi.org/10.3389/fpubh.2026.1767197 (Description of a free web-based cervical cancer risk self-assessment tool deployed by the Croatian Institute of Public Health, accessed nearly 9,000 times in its first two years, with a high completion rate; provides a model for digital health literacy in cervical cancer prevention.)
• Bonar G, Cameron S. "Human papillomavirus vaccination and cervical screening uptake among women presenting for abortion: exploring opportunities for health care interventions." BMJ Sexual & Reproductive Health. April 13, 2026. PMID 41224642. https://doi.org/10.1136/bmjsrh-2025-203018 (Retrospective study from Edinburgh, Scotland, finding that 12.5% of women under 25 presenting for abortion were unvaccinated against HPV and 28.3% of those over 25 had never been screened for cervical cancer - with three-quarters of each group making an in-person clinic visit, identifying abortion care settings as a potential opportunity for catch-up prevention services.)

Papers Excluded Due to Licensing Restrictions

The following papers address topics relevant to the community and may be openly available but have licensing terms that are unclear or do not permit inclusion in this digest.

• [Authors unavailable from metadata]. "DUSP14 inhibits cervical cancer cells via TAK1 and NLRP3 pathways." Journal of International Medical Research. April 28, 2026. PMID 42050913. (Excluded: License unconfirmed - Wolters Kluwer journal. Topic: Preclinical study of DUSP14 as a potential tumor suppressor in cervical cancer through TAK1 and NLRP3 signaling pathways.)
• [Authors unavailable]. "Two-phase designs for cost-effective evaluation of cancer screening tests." Biometrics (Oxford University Press). April 9, 2026. PMID 42043340. (Excluded: License unconfirmed - OUP subscription journal. Topic: Statistical methodology for designing cost-effective cervical cancer screening test evaluations.)
• [Authors unavailable]. "Cost-effectiveness of p16/Ki-67 dual staining in cervical lesion detection in Colombia." Revista Colombiana de Obstetricia y Ginecología. April 18, 2026. PMID 42049009. (Excluded: License unconfirmed. Topic: Health economic analysis of p16/Ki-67 dual biomarker staining as a triage method for cervical lesion detection in a Colombian population.)
• [Authors unavailable]. "PIK3CA mutant cervical cancer selectively suppressed by PI3Kα inhibition; cooperates with HPV-directed T cell therapy." Neoplasia. April 13, 2026. PMID 41980433. (Excluded: License unconfirmed. Topic: Preclinical study combining PI3K inhibition with HPV-targeted T cell immunotherapy in PIK3CA-mutant cervical cancer models.)
• [Authors unavailable]. "It Feels Like Another Thing Cancer Took From Me - Financial toxicity in cervical cancer patients, New Zealand." Journal of Medical Imaging and Radiation Oncology (Wiley). April 8, 2026. PMID 41952311. (Excluded: License unconfirmed - Wiley hybrid journal. Topic: Qualitative study of financial toxicity experienced by people with cervical cancer in New Zealand.)
• [Authors unavailable]. "Integrating HPV and HIV Services Into a One-Stop Breast Cancer Early Detection Clinic in Zambia." JCO Global Oncology. April 3, 2026. PMID 41931719. (Excluded: Likely CC BY-NC-ND - JCO Global Oncology. Topic: Feasibility study of integrating HPV and HIV services into an existing breast cancer detection clinic in Zambia.)

(The following papers were excluded due to confirmed or likely non-permitted licenses at the journal or article level. Full citation details for all 67 excluded papers are listed below in abbreviated form. Where full author lists were not retrievable from open metadata, journal names and topics are provided.)

Papers excluded from Wolters Kluwer subscription journals (confirmed "All rights reserved" or unconfirmed per-article license): PMID 42080610, plus multiple papers in Journal of Immunotherapy, Clinical Nuclear Medicine, JAIDS, Journal of Lower Genital Tract Disease, and Journal of International Medical Research.

Papers excluded from Elsevier subscription or hybrid journals where a CC license was not confirmed per article: Papers in BBRC (×2), Journal of Cancer Policy, Photodiagnosis and Photodynamic Therapy, Gynecologic Oncology (×2), Vaccine (×4), International Journal of Infectious Diseases, Supportive Care in Cancer, Cancer Research (×2), Molecular Cancer Therapeutics, Cancer Research Communications, and Lancet Regional Health Americas (1 paper with per-article CC BY-NC-ND possible). PMID 42069248, 42044725 confirmed "All rights reserved."

Papers excluded from Wiley subscription or hybrid journals where a CC license was not confirmed per article: Papers in Journal of Medical Screening, Journal of Medical Virology (×8), Medical Physics (×2), Journal of Applied Clinical Medical Physics, Human Vaccines & Immunotherapeutics (×2, unconfirmed), Cancer Medicine (×2), International Journal of Gynaecology and Obstetrics, British Journal of Nursing, Journal of Obstetrics and Gynaecology Research, Medical Journal of Australia, Clinical and Translational Medicine, and Journal of Medical Imaging and Radiation Oncology. PMID 41952311.

Papers excluded from Oxford University Press subscription or hybrid journals: Papers in Journal of Medical Screening, Journal of Infectious Diseases, JNCI Monographs, and Biometrics. PMID 42043340.

Papers excluded from proprietary Chinese journals (confirmed or likely "All rights reserved"): Two papers in Zhonghua Yi Xue Za Zhi.

Additional excluded papers: PMID 41931719 (JCO Global Oncology, likely CC BY-NC-ND); PMID 41980433 (Neoplasia, unconfirmed); PMID 42049009 (Revista Colombiana de Obstetricia y Ginecología, unconfirmed); papers in Anticancer Research (×2, confirmed "All rights reserved"); papers in Future Oncology, Cancer Causes & Control, Clinical Laboratory, and Human Vaccines & Immunotherapeutics (unconfirmed articles). Additional PMIDs with confirmed "All rights reserved": 42000372, 42000628, 41965976, 41983477, 42008725, 41895773, 41895747, 41457279, 41239758, 41706801, 41701941.